"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
| Descriptor ID |
D000995
|
| MeSH Number(s) |
D27.505.954.122.085.255
|
| Concept/Terms |
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
|
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 4 | 0 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Discovery and Biosynthesis of Persiathiacins: Unusual Polyglycosylated Thiopeptides Active Against Multidrug Resistant Tuberculosis. ACS Infect Dis. 2024 Sep 13; 10(9):3378-3391.
-
Possible role for acetylcysteine as a treatment for acute liver failure secondary to antitubercular medication use. Am J Health Syst Pharm. 2020 09 04; 77(18):1482-1487.
-
Haemophagocytic lymphohistiocytosis (HLH) secondary to miliary tuberculosis. Indian J Tuberc. 2020 Jul; 67(3):366-370.
-
Mechanistic investigation of resistance via drug-inactivating enzymes in Mycobacterium tuberculosis. Drug Metab Rev. 2018 11; 50(4):448-465.
-
Chemical classes targeting energy supplying GyrB domain of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2018 12; 113:43-54.
-
Pharmacophore modeling and molecular dynamics approach to identify putative DNA Gyrase B inhibitors for resistant tuberculosis. J Cell Biochem. 2019 03; 120(3):3149-3159.
-
In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis. Tuberculosis (Edinb). 2018 09; 112:83-88.
-
Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs. J Pharm Sci. 2017 01; 106(1):331-337.
-
Macronutrient intake and body composition changes during anti-tuberculosis therapy in adults. Clin Nutr. 2016 Feb; 35(1):205-212.
-
Liquid chromatographic determination of CPZEN-45, a novel anti-tubercular drug, in biological samples. J Pharm Biomed Anal. 2014 Jan; 88:370-6.